Mylan tops profit estimates on drug launches
Generic drugmaker Mylan NV beat Wall Street estimates for third-quarter profit on Tuesday, benefiting from drug launches such as Wixela and Fulphila, sending its shares up 2% before the opening bell.
Generic drugmaker Mylan NV beat Wall Street estimates for third-quarter profit on Tuesday, benefiting from drug launches such as Wixela and Fulphila, sending its shares up 2% before the opening bell.